Ground News

Don't Just Read the News, Understand It.

Mainz Biomed image

News from Mainz Biomed

See all of Mainz Biomed news coverage in one place. Discover how Mainz Biomed’s media bias informs their coverage and compare with thousands of other news outlets.

We’ve discovered 9 headlines written by Mainz Biomed during the past 3 months.

We’ve assigned a media bias rating of unknown to Mainz Biomed. You can read more about our methodology here.

Mainz Biomed’s aggregated factuality score is Unknown. Factuality is assigned by combining fact check, credibility, and reliability ratings from Ad Fontes Media and Media Bias/Fact Check.

Information about Mainz Biomed

Where is Mainz Biomed located?Mainz Biomed's Website

Media Bias Ratings

Do you diasgree?

Edit bias

Learn more about Media Bias Ratings.

Factuality

Learn more about Factuality Ratings

Reveal Factuality Ratings by upgrading to a Premium account.

Tap Upgrade to explore subscription options to meet all your reading needs.

Ownership

Learn more about Ownership categories

Reveal Ownership Data by upgrading to a Vantage account.

Tap Upgrade to explore subscription options to meet all your reading needs.

Top Mainz Biomed News

Mainz Begins Next Phase of Project to Develop Pancreatic Cancer Blood Test

Mainz Begins Next Phase of Project to Develop Pancreatic Cancer Blood Test

Mainz Biomed has started the feasibility phase of the PancAlert project to develop a pancreatic cancer screening test.The post Mainz begins next phase of project to develop pancreatic cancer blood test appeared first on Medical Device Network.See the Story

Mainz Biomed announces technology partnership with EDX Medical Group - Mainz Biomed

BERKELEY, USA and MAINZ, Germany – April 29, 2025 – Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular diagnostics company specializing in early cancer detection, announced a technology partnership with the UK-based EDX Medical Group plc (AQSE: EDX). EDX Medical develops innovative digital diagnostic products and services to support personalized treatments for cancer, cardiovascular, and infectious diseases. Under the…Mainz · Mainz Read Article

Mainz Biomed Provides First Quarter 2025 Corporate Update and Path to FDA Premarket Approval - Mainz Biomed

BERKELEY, US – MAINZ, Germany – April 28, 2025 — Mainz Biomed N.V. (NASDAQ: MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, today reviewed its major accomplishments of the first quarter of 2025, and provided an outlook on its path to FDA premarket approval. During the first quarter of 2025: Path to FDA premarket approval: The Company enrolled the first patient into …Mainz · Mainz Read Article

Mainz Biomed announces financial results for 2024 and provides information on corporate development - Mainz Biomed

Revenue from sales through its laboratory partner network increased by 33% year-on-year, reflecting strong demand for ColoAlert® in Europe Operating loss decreased by 30% and net loss by 18%, the result of targeted cost-cutting measures and a stronger strategic focus Strategic partnerships with industry-leading companies mark significant progress The company reports on its first achievements in fiscal year 2025 BERKELEY, USA and MAINZ, Germany –…Mainz · Mainz Read Article

Mainz enrols first subject in study to evaluate colorectal cancer test

Mainz Biomed has enrolled the first subject in its eAArly DETECT 2 feasibility study, aimed at evaluating colorectal cancer (CRC) test.The post Mainz enrols first subject in study to evaluate colorectal cancer test appeared first on Medical Device Network.Cancer · Mainz See the Story

You've scrolled to the bottom of the feed, there are no more stories.